Patents by Inventor Woo Ick Jang

Woo Ick Jang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210177945
    Abstract: Provided is a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency. Particularly, the present disclosure relates to a pharmaceutical composition for treating growth hormone deficiency, containing a recombinant hGH GX-H9 and a pharmaceutically acceptable carrier, in which the recombinant GX-H9 is administered once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient. Further, the present disclosure relates to a method for treating growth hormone deficiency including administering an recombinant hGH GX-H9 to a patient with growth hormone deficiency once a week with a dosage of 0.1 to 0.3 mg per weight kg of the patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 17, 2021
    Inventors: Tae Kyung Kim, Young_Joo Ahn, Jung Won Woo, Ji-Eun Cha, Joan Yoon Ji Lee, Woo Ick Jang
  • Patent number: 10499982
    Abstract: A catheter for denervation includes a catheter body extending in one direction to have a proximal end and a distal end and having an inner space formed along the longitudinal direction thereof, a movable member provided at the distal end of the catheter body to be movable along the longitudinal direction of the catheter body, an operating member having a distal end connected to the movable member to move the movable member, a plurality of support members having one end connected to a terminal of the catheter body and the other end connected to the movable member, wherein when the movable member moves to decrease a distance between the terminal of the catheter body and the movable member, at least a partial portion of the plurality of support members is bent so that the bending portion moves away from the catheter body, a plurality of electrodes respectively provided at the bending portion of the plurality of support members to generate heat, and a lead wire respectively electrically connected to the plurality
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 10, 2019
    Assignee: HANDOK KALOS MEDICAL INC.
    Inventors: In-Je Hwang, Hae-Won Jang, Seung-Woo Song, Woo-Ick Jang
  • Publication number: 20190224281
    Abstract: A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.
    Type: Application
    Filed: August 30, 2017
    Publication date: July 25, 2019
    Applicants: GENEXINE, INC., HANDOK INC.
    Inventors: Tae Kyung KIM, Jung Won WOO, Joan Yoon Ji LEE, Young-Joo AHN, Ji-Eun CHA, Hyou Young RHIM, Woo Ick JANG
  • Publication number: 20150351835
    Abstract: A catheter for denervation includes a catheter body extending in one direction to have a proximal end and a distal end and having an inner space formed along the longitudinal direction thereof, a movable member provided at the distal end of the catheter body to be movable along the longitudinal direction of the catheter body, an operating member having a distal end connected to the movable member to move the movable member, a plurality of support members having one end connected to a terminal of the catheter body and the other end connected to the movable member, wherein when the movable member moves to decrease a distance between the terminal of the catheter body and the movable member, at least a partial portion of the plurality of support members is bent so that the bending portion moves away from the catheter body, a plurality of electrodes respectively provided at the bending portion of the plurality of support members to generate heat, and a lead wire respectively electrically connected to the plurality
    Type: Application
    Filed: February 5, 2014
    Publication date: December 10, 2015
    Applicant: HANDOK INC.
    Inventors: In-Je Hwang, Hae-Won Jang, Seung-Woo Song, Woo-Ick Jang
  • Patent number: 8883134
    Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: November 11, 2014
    Assignees: Handok Pharmaceuticals, Inc., Genexine, Inc.
    Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
  • Publication number: 20130217864
    Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 22, 2013
    Applicant: HANDOK PHARMACEUTICALS CO., LTD.
    Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang